Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Clinical Cancer Research
Clinical Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Table of Contents

  • Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A.
    J van Asperen, O van Tellingen, M A van der Valk, M Rozenhart and J H Beijnen
    Clin Cancer Res October 1 1998 4 (10) 2293-2297;

  • Response of MCF7 human breast cancer to tamoxifen: evaluation by the three-time-point, contrast-enhanced magnetic resonance imaging method.
    E Furman-Haran, D Grobgeld, R Margalit and H Degani
    Clin Cancer Res October 1 1998 4 (10) 2299-2304;

  • Angiogenic activity of cervical carcinoma: assessment by functional magnetic resonance imaging-based parameters and a histomorphological approach in correlation with disease outcome.
    H Hawighorst, W Weikel, P G Knapstein, M V Knopp, I Zuna, S O Schönberg, P Vaupel and G van Kaick
    Clin Cancer Res October 1 1998 4 (10) 2305-2312;

  • Similar bioavailability of single-dose oral and intravenous mesna in the blood and urine of healthy human subjects.
    M P Goren, J M Houle, D A Bush, J T Li, C E Newman and W P Brade
    Clin Cancer Res October 1 1998 4 (10) 2313-2320;

  • Phase I trial of cremophor EL with bolus doxorubicin.
    M J Millward, L K Webster, D Rischin, K H Stokes, G C Toner, J F Bishop, I N Olver, B M Linahan, M E Linsenmeyer and D M Woodcock
    Clin Cancer Res October 1 1998 4 (10) 2321-2329;

  • bcl-2 but not p53 expression is associated with resistance to chemotherapy in advanced breast cancer.
    A Bonetti, M Zaninelli, R Leone, G L Cetto, G Pelosi, S Biolo, A Menghi, E Manfrin, F Bonetti and Q Piubello
    Clin Cancer Res October 1 1998 4 (10) 2331-2336;

  • Signal transduction abnormalities in T lymphocytes from patients with advanced renal carcinoma: clinical relevance and effects of cytokine therapy.
    R M Bukowski, P Rayman, R Uzzo, T Bloom, K Sandstrom, D Peereboom, T Olencki, G T Budd, D McLain, P Elson, A Novick and J H Finke
    Clin Cancer Res October 1 1998 4 (10) 2337-2347;

  • Cellular but not plasma pharmacokinetics of lometrexol correlate with the occurrence of cumulative hematological toxicity.
    T W Synold, E M Newman, M Carroll, F M Muggia, S Groshen, K Johnson and J H Doroshow
    Clin Cancer Res October 1 1998 4 (10) 2349-2355;

  • Augmented capillary leak during isolated hepatic perfusion (IHP) occurs via tumor necrosis factor-independent mechanisms.
    H R Alexander, C K Brown, D L Bartlett, S K Libutti, W D Figg, S Raje and E Turner
    Clin Cancer Res October 1 1998 4 (10) 2357-2362;

  • Enhancement of cell-mediated immunity in melanoma patients immunized with murine anti-idiotypic monoclonal antibodies (MELIMMUNE) that mimic the high molecular weight proteoglycan antigen.
    M W Pride, S Shuey, A Grillo-Lopez, G Braslawsky, M Ross, S S Legha, O Eton, A Buzaid, C Ioannides and J L Murray
    Clin Cancer Res October 1 1998 4 (10) 2363-2370;

  • High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil.
    R Metzger, K Danenberg, C G Leichman, D Salonga, E L Schwartz, S Wadler, H J Lenz, S Groshen, L Leichman and P V Danenberg
    Clin Cancer Res October 1 1998 4 (10) 2371-2376;

  • Overexpression of cyclin D1 is associated with poor prognosis in extremity soft-tissue sarcomas.
    S H Kim, J J Lewis, M F Brennan, J M Woodruff, M Dudas and C Cordon-Cardo
    Clin Cancer Res October 1 1998 4 (10) 2377-2382;

  • Epidermal growth factor receptor and labeling index are independent prognostic factors in glial tumor outcome.
    M C Etienne, J L Formento, C Lebrun-Frenay, J Gioanni, M Chatel, P Paquis, C Bernard, A Courdi, R J Bensadoun, J P Pignol, M Francoual, P Grellier, M Frenay and G Milano
    Clin Cancer Res October 1 1998 4 (10) 2383-2390;

  • Activated calphostin C cytotoxicity is independent of p53 status and in vivo metastatic potential.
    Z Dubauskas, T P Beck, S J Chmura, D A Kovar, M M Kadkhodaian, M Shrivastav, T Chung, W M Stadler and C W Rinker-Schaeffer
    Clin Cancer Res October 1 1998 4 (10) 2391-2398;

  • Ex vivo activity of methotrexate versus novel antifolate inhibitors of dihydrofolate reductase and thymidylate synthase against childhood leukemia cells.
    R Mauritz, M W Bekkenk, M G Rots, R Pieters, E Mini, C H van Zantwijk, A J Veerman, G J Peters and G Jansen
    Clin Cancer Res October 1 1998 4 (10) 2399-2410;

  • Polymorphism within the cyclin D1 gene is associated with prognosis in patients with squamous cell carcinoma of the head and neck.
    C Matthias, K Branigan, V Jahnke, K Leder, J Haas, J Heighway, P W Jones, R C Strange, A A Fryer and P R Hoban
    Clin Cancer Res October 1 1998 4 (10) 2411-2418;

  • Expression of cadherin-6 as a novel diagnostic tool to predict prognosis of patients with E-cadherin-absent renal cell carcinoma.
    T Shimazui, E Oosterwijk, H Akaza, P Bringuier, E Ruijter, H van Berkel, J O Wakka, A van Bokhoven, F M Debruyne and J A Schalken
    Clin Cancer Res October 1 1998 4 (10) 2419-2424;

  • Differential interleukin 12 responsiveness for interferon gamma production in advanced stages of cancer patients correlates with performance status.
    K Uno, J Setoguchi, M Tanigawa, A Kishi, M Ogawa, H Saotome, H Fujiwara and T Kishida
    Clin Cancer Res October 1 1998 4 (10) 2425-2432;

  • Frequency of germline and somatic BRCA1 mutations in ovarian cancer.
    A Berchuck, K A Heron, M E Carney, J M Lancaster, E G Fraser, V L Vinson, A M Deffenbaugh, A Miron, J R Marks, P A Futreal and T S Frank
    Clin Cancer Res October 1 1998 4 (10) 2433-2437;

  • Association of glutathione S-transferase GSTM1 and GSTT1 null genotypes with clinical outcome in epithelial ovarian cancer.
    R E Howells, C W Redman, K K Dhar, P Sarhanis, C Musgrove, P W Jones, J Alldersea, A A Fryer, P R Hoban and R C Strange
    Clin Cancer Res October 1 1998 4 (10) 2439-2445;

  • Allelic deletion analyses of MMAC/PTEN and DMBT1 loci in gliomas: relationship to prognostic significance.
    H Lin, M L Bondy, L A Langford, K R Hess, G L Delclos, X Wu, W Chan, M A Pershouse, W K Yung and P A Steck
    Clin Cancer Res October 1 1998 4 (10) 2447-2454;

  • Basic fibroblast growth factor enhancement of adenovirus-mediated delivery of the herpes simplex virus thymidine kinase gene results in augmented therapeutic benefit in a murine model of ovarian cancer.
    C Rancourt, B E Rogers, B A Sosnowski, M Wang, A Piché, G F Pierce, R D Alvarez, G P Siegal, J T Douglas and D T Curiel
    Clin Cancer Res October 1 1998 4 (10) 2455-2461;

  • Inhibition of human glioblastoma cell adhesion and invasion by 4-(4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P131) and 4-(3'-bromo-4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P154).
    R K Narla, X P Liu, D Klis and F M Uckun
    Clin Cancer Res October 1 1998 4 (10) 2463-2471;

  • Effect of the combined treatment with 5-fluorouracil, gamma-interferon or folinic acid on carcinoembryonic antigen expression in colon cancer cells.
    A Aquino, S P Prete, J W Greiner, A Giuliani, G Graziani, M Turriziani, R De Filippi, G Masci, E Bonmassar and L De Vecchis
    Clin Cancer Res October 1 1998 4 (10) 2473-2481;

  • Comparison of 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-2-[p-(bromoacetamido)benzyl]-DOTA-ChL6 in breast cancer xenografts.
    G L DeNardo, L A Kroger, C F Meares, C M Richman, Q Salako, S Shen, K R Lamborn, J J Peterson, L A Miers, G R Zhong and S J DeNardo
    Clin Cancer Res October 1 1998 4 (10) 2483-2490;

  • Multifocal renal cell carcinoma: evidence for a common clonal origin.
    H Miyake, H Nakamura, I Hara, K Gohji, S Arakawa, S Kamidono and H Saya
    Clin Cancer Res October 1 1998 4 (10) 2491-2494;

  • Human IgG2 constant region enhances in vivo stability of anti-tenascin antibody 81C6 compared with its murine parent.
    C J Reist, D D Bigner and M R Zalutsky
    Clin Cancer Res October 1 1998 4 (10) 2495-2502;

  • Enhanced growth inhibition and differentiation of fluorodeoxyuridine-treated human colon carcinoma cells by phenylbutyrate.
    Y Huang and S Waxman
    Clin Cancer Res October 1 1998 4 (10) 2503-2509;

  • Complement factor H or a related protein is a marker for transitional cell cancer of the bladder.
    R Kinders, T Jones, R Root, C Bruce, H Murchison, M Corey, L Williams, D Enfield and G M Hass
    Clin Cancer Res October 1 1998 4 (10) 2511-2520;

  • Bystander effect in the adenovirus-mediated wild-type p53 gene therapy model of human squamous cell carcinoma of the head and neck.
    D K Frank, M J Frederick, T J Liu and G L Clayman
    Clin Cancer Res October 1 1998 4 (10) 2521-2528;

  • Search for the optimal schedule for the oxaliplatin/5-fluorouracil association modulated or not by folinic acid: preclinical data.
    J L Fischel, M C Etienne, P Formento and G Milano
    Clin Cancer Res October 1 1998 4 (10) 2529-2535;

  • A four-hour topotecan infusion achieves cytotoxic exposure throughout the neuraxis in the nonhuman primate model: implications for treatment of children with metastatic medulloblastoma.
    W C Zamboni, A J Gajjar, T D Mandrell, S L Einhaus, M K Danks, W P Rogers, R L Heideman, P J Houghton and C F Stewart
    Clin Cancer Res October 1 1998 4 (10) 2537-2544;

  • Cell surface density of p185(c-erbB-2) determines susceptibility to anti-p185(c-erbB-2)-ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170(EGFR)-RTA in ovarian cancer cells.
    G S Dean, L Pusztai, F J Xu, K O'Briant, K DeSombre, M Conaway, C M Boyer, J Mendelsohn and R C Bast Jr
    Clin Cancer Res October 1 1998 4 (10) 2545-2550;

  • Suppression of human prostate carcinoma metastases in severe combined immunodeficient mice by interleukin 2 immunocytokine therapy.
    C S Dolman, B M Mueller, H N Lode, R Xiang, S D Gillies and R A Reisfeld
    Clin Cancer Res October 1 1998 4 (10) 2551-2557;

  • Annexin I degradation in bronchoalveolar lavage fluids from healthy smokers: a possible mechanism of inflammation.
    J K Vishwanatha, R G Davis, I Rubinstein and A Floreani
    Clin Cancer Res October 1 1998 4 (10) 2559-2564;

  • Expression of mouse mammary tumor virus-like env gene sequences in human breast cancer.
    Y Wang, V Go, J F Holland, S M Melana and B G Pogo
    Clin Cancer Res October 1 1998 4 (10) 2565-2568;

  • Correspondence re: S. M. Melana et al., Inhibition of cell growth and telomerase activity of breast cancer cells in vitro by 3'-azido-3'-deoxythymidine. Clin. Cancer Res., 4: 693-696, 1998.
    O A Olivero and D E Gomez
    Clin Cancer Res October 1 1998 4 (10) 2569-2570;

Back to top
PreviousNext
October 1998
Volume 4, Issue 10
  • Table of Contents
  • Table of Contents (PDF)
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)

Sign up for alerts

Advertisement
  • Most Cited
  • Most Read
Loading
  • Immune Checkpoint Blockade Requires Macrophage CXCL9/CXCL10
  • PDAC and GATA6 Expression
  • Characterization of Glioblastoma Patient-Derived Xenografts
  • Guadecitabine and Carboplatin in Ovarian Cancer
  • Toxicity Management Affects Checkpoint Inhibitor Efficacy
More...
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • CCR Focus Archive
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Clinical Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Clinical Cancer Research
eISSN: 1557-3265
ISSN: 1078-0432

Advertisement